ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Daybue Sales and ...
ACADIA Pharmaceuticals Inc (ACAD) posted $342 million in quarterly revenue and lifted its Daybue outlook, even as the remlifanserin Phase 2 study narrowly missed statistical significance. Related Stocks: ACAD ,